Collplant Holdings (CLPT)

Business description

CollPlant is an Israel-based regenerative medicine company. It is focused on developing and commercialising tissue repair products with its plant-based technology, rhCollagen. It has two products on the market, VergenixSTR and VergenixFG.

Stock data

Market cap.NIS63.6m
Last closeNIS0.49
High / Low (52 weeks)NIS1.3 / NIS0.3
Stock market listingTel Aviv Stock Exchange
Forecast net debt (NISm)1.3
Forecast gearing ratio (%)1155
TeamHealthcare
SectorPharmaceutical & healthcare

Price performance

%1m3m12m
Actual36.153.4(60.6)
Relative *33.551.1(61.4)

* % Relative to local index

Other companies in sector Show

4SC aap Implantate
Aastrom Biosciences AB Science
Abcam Abivax SA
Ablynx Abzena
Acarix Achillion Pharmaceuticals
Acorda Therapeutics Actinium Pharmaceuticals
Active Biotech Acucela
Addex Therapeutics Adherium
Advanced Medical Solutions Aegerion Pharmaceuticals
Aeterna Zentaris AFT Pharmaceuticals
Agennix Akari Therapeutics
Alchemia Alexza Pharmaceuticals
Algeta Alimera Sciences
ALK Abello Alkermes
Allergy Therapeutics Alliance Pharma
Allium Medical Solutions Alnylam Pharmaceuticals
Amarantus BioScience Amarin
Amplifon AmpliPhi Biosciences
Angle Animalcare Group
Anteo Diagnostics Anthera Pharmaceuticals
Aratana Therapeutics Ardea Biosciences
Ardelyx Arena Pharmaceuticals
arGEN-X Argos Therapeutics
Ariad Pharmaceuticals Arix Bioscience
Ark Therapeutics Group ArQule
Array BioPharma Arrowhead Research Corporation
Ascendis Pharma Astex Pharmaceuticals
Athersys Atossa Genetics
Avacta Group Avalanche Biotechnologies
AVEO Pharmaceuticals Avita Medical
Balda Basilea Pharmaceutica
Bavarian Nordic BB Healthcare Trust
Bellus Health Benitec Biopharma
BioCryst Pharmaceuticals BioInvent
BioLight Life Sciences BioLineRx
Biondvax Pharmaceuticals Bionomics
Bionor Pharma Biota Holdings
Biotie Therapies Corp Biotron
Bluebird Bio Bone Therapeutics
BrainStorm Cell Therapeutics BTG
C4X Discovery Holdings Can-Fite BioPharma
Capstone Therapeutics Carmat
Cell Therapy Celldex Therapeutics
Cellectis Cellular Biomedicine Group
Celyad Cerulean Pharma
Circadian Technologies Clavis Pharma
Cleveland BioLabs Clinigen Group
Clinuvel co.don AG
Consort Medical Corium International
Crescendo Crossject
Curis Cytori Therapeutics
Cytos Biotechnology CytRx Corporation
DBV Technologies Dechra Pharmaceuticals
Delcath Systems Deltex Medical
Derma Sciences DiaSorin
Diaxonhit e-Therapeutics
Egalet Corporation EKF Diagnostics
Emergent BioSolutions Endocyte
Epigenomics Erytech Pharma
Esperion Therapeutics Evotec
Exact Sciences Exelixis
Factor Therapeutics Formycon
Forward Pharma Fresenius SE & Co. KGaA
Futura Medical Galapagos
Galmed Pharmaceuticals Genedrive
Genfit Genkyotex
Genmab GeoVax
GI Dynamics Gilead Sciences
GNI Group Ltd GW Pharmaceuticals
Halozyme Therapeutics Horizon Discovery
Hutchison China MediTech Hybrigenics
iCo Therapeutics Idenix
Immune Pharmaceuticals Immunicum
Immunodiagnostic Systems Holdings Immunovia
ImmuPharma Imprimis Pharmaceuticals
Imugene Incyte Corporation
Infinity Pharmaceuticals Innate Pharma
Insmed Intec Pharma
International Stem Cell Invion
Ion Beam Applications Ipsogen
Iridex Ironwood Pharmaceuticals
Islet Sciences Ixico
KaloBios Pharmaceuticals Karolinska Development
Keryx Biopharmaceuticals Kiadis Pharma
LCA-Vision LeMaitre Vascular
Lifeline Scientific LifeWatch
Ligand Pharmaceuticals Lipocine
Lombard Medical Technologies MagForce
Mast Therapeutics Medcom Tech
Medicago MediciNova
Medigene Medivir
Merrimack Pharmaceuticals Merrion Pharmaceuticals
Mesoblast MethylGene
Midatech Pharma MISSION Therapeutics
Molecular Partners MolMed
Mologen AG Momenta Pharmaceuticals
MorphoSys Nanobiotix
Nanosonics Navidea Biopharmaceuticals
Nektar Therapeutics NeoStem
Neovacs NetScientific
NeuroVive Pharmaceutical Newron Pharmaceuticals
Nexstim NicOx
NMC Health NorDiag
Nordion NovaBay Pharmaceuticals
Novacyt Novogen
NPS Pharmaceuticals Nuevolution
Ocata Therapeutics Omega Diagnostics Group
Omeros Corporation OncoGenex Pharmaceuticals
Oncolytics Biotech Inc OncoMed Pharmaceuticals
Onconova Therapeutics Oncothyreon
Onxeo Onyx Pharmaceuticals
Opexa Therapeutics OPMEDIC Group
Optos Orexigen Therapeutics
Orexo Oryzon Genomics
Ossur OvaScience
Oxford BioMedica Pacific Edge
Paion Paladin Labs
Patheon PDL BioPharma
Pharmacyclics PharmaMar
Pharmaxis Pharming Group
Photocure Phylogica
Pixium Vision Pluristem Therapeutics
Prescient Therapeutics Prima BioMed
Probiodrug ProMetic Life Sciences
Prosensa Proteome Sciences
PsiOxus QRxPharma
Quantum Genomics Quantum Pharmaceuticals
RedHill Biopharma Regeneus
Relmada Therapeutics ReNeuron Group
Resverlogix REVA Medical
ROVI Laboratorios Farmaceuticos RXi Pharmaceuticals
Sangamo BioSciences Sarepta Therapeutics
Sartorius Scancell
Selvita Shire
Silence Therapeutics Simavita
Sinclair Pharma Sirtex Medical
Skyepharma Smith & Nephew
Sobi Sosei Group Corporation
Source Bioscience SQI Diagnostics
Stallergenes StemCells
Stentys Stratec Biomedical
Sucampo Pharmaceuticals Sunesis Pharmaceuticals
Surgical Innovations Sygnis
SymBio Pharmaceuticals Synairgen
Synergy Health Synta Pharmaceuticals
TearLab Corp Tekmira
TESARO Theraclion
Threshold Pharmaceuticals ThromboGenics
TiGenix Tissue Regenix
Tissue Therapies Titan Pharmaceuticals
Tonix Pharmaceuticals Topotarget
Touchstone Innovations Transgene
Trillium Therapeutics Trimel Pharmaceuticals
TruScreen Ltd TxCell
UCB UDG Healthcare
uniQure NV Universal Biosensors
VBI Vaccines Vectura
Verastem Verisante Technology
Vernalis Verona Pharma
Vertex Pharmaceuticals Viralytics
ViroPharma Vivalis
Vivus VolitionRx
WaferGen Biosystems Wilex
Xbrane Biopharma Xencor
Zafgen Zealand Pharma
Ziopharm Oncology

Company news

BRIEF-Collplant signs exclusive distribution agreement with Arthrex for ...

Tue, 08 Nov 2016 14:37:30 GMT

Collplant Holdings Ltd (CQPTY: OTCQX International) | CollPlant Reports ...

Tue, 11 Apr 2017 15:45:00 GMT

Collplant Holdings Ltd (CQPTY: OTCQX International) | CollPlant Provides ...

Thu, 30 Mar 2017 10:18:45 GMT

CollPlant signs distribution agreement with Arthrex

Wed, 09 Nov 2016 09:56:15 GMT

CollPlant reports commercialization underway

Sun, 02 Apr 2017 08:37:30 GMT

Y/E Dec Revenue (NISm) EBITDA (NISm) PBT (NISm) EPS (NIS) P/E (x) P/CF (x)
2015A 0.0 (18.0) (18.7) (22.03) N/A N/A
2016A 0.3 (27.0) (27.9) (27.72) N/A N/A
2017E 1.3 (15.5) (16.3) (12.72) N/A N/A
2018E 2.9 (17.2) (17.8) (13.86) N/A N/A

Last updated on 04/04/2017

Investment summary

2016 was an important year for CollPlant as it completed a clinical study and received its CE approval for VergenixSTR, entered into an exclusive distribution agreement with Arthrex to commercialise VergenixSTR in EMEA and launched VergenixFG in Europe. We expect CollPlant to build on this progress in 2017 by increasing its distribution of VergenixFG and orders from Arthrex, alongside developing its earlier-stage rhCollagen technology BioInk for 3D printing of organs and tissues. We note that there is a fund raising requirement this year. We have slightly increased our rNPV to $66m (NIS244m) on FY16 results having also rolled the model forward.

Last updated on 04/04/2017

Key management

Yehiel Tal, CEO
Eran Rotem, CFO

Company address

3 Sapir Street
Weizmann Science Park, P.o.B 4132
Ness-Ziona
Nes Ziona
74140
Israel
972-73-232-5600
View website